Literature DB >> 3302004

Prevention of duodenal ulcer occurrence. Double-blind comparison of ranitidine and cimetidine.

T D Bolin, A E Davis, B Billington.   

Abstract

We compared ranitidine and cimetidine in maintenance therapy to prevent duodenal ulcer recurrence over a period of 24 months. Endoscopic examination at the end of 12 months showed that the ulcers of 26 of 31 patients (84%) on ranitidine in a dose of 150 mg remained healed and of 10 of 13 (77%) patients on cimetidine in a dose of 400 mg at night remained healed. Thirty-four patients continued in an open evaluation of ranitidine in a dose of 150 mg at night for a further 12-month period, and during this time there were four further recurrences. Life table estimates of duodenal ulcer recurrence during the 2-year period showed no significant difference between the two forms of treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3302004     DOI: 10.1097/00004836-198706000-00013

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  2 in total

Review 1.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

2.  Two year maintenance treatment of duodenal ulcer disease with ranitidine 150 mg: a prospective multicentre randomised study. GEMUD (Groupe d'Etude de la Maladie Ulcéreuse Duodénale).

Authors:  P Ruszniewski; A Slama; M Pappo; M Mignon
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.